Audeo Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on utilizing its hyaluronic acid chemotransport technology (HyACT) to target cancer drugs primarily to tumor cells to enhance drug activity. HyACT is a platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. HyACT product candidate, HA-Irinotecan, as of June 30, 2012, was in a pivotal Phase III clinical trial for metastatic colorectal cancer (mCRC). HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer (SCLC). The Company also had two other HyACT product candidates that has completed Phase I clinical trials. The Company�s product candidate is HyACT-targeted irinotecan (HA-Irinotecan) for the treatment of mCRC. HyACT uses hyaluronic acid (HA), which delivers additional drug to the tumor and promotes uptake of the drug into the tumor cells.